Evidence map›Paper›PMID 39376007›Full record

ArticleAmerican journal of men's health

KLF1 Activates RAC3 to Mediate Fatty Acid Synthesis and Enhance Cisplatin Resistance in Bladder Cancer Cells.

Lide Song, Qi Xu, Rong Chen, Wanghong Sun, Jianfei Zhan

Abstract read
In one paragraph

Article in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lide SongDepartment of Urology, Zhuji People's Hospital, Zhuji, China.
Qi XuDepartment of Urology, Zhuji People's Hospital, Zhuji, China.
Rong ChenDepartment of Urology, Zhuji People's Hospital, Zhuji, China.
Wanghong SunDepartment of Urology, Zhuji People's Hospital, Zhuji, China.
Jianfei ZhanDepartment of Urology, Zhuji People's Hospital, Zhuji, China.ORCID 0009-0006-0653-9092

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While cisplatin remains a frontline treatment for bladder cancer (BCa), the onset of resistance greatly hampers its effectiveness. RAC3 is closely linked to chemoresistance in cancer cells, but its specific role in cisplatin resistance within BCa is still elusive. RAC3 expression in BCa was analyzed using bioinformatics and quantitative polymerase chain reaction (qPCR). The gene set enrichment analysis (GSEA) identified RAC3-enriched pathways and the correlation between RAC3 and fatty acid synthase (FASN), a gene involved in fatty acid synthesis. Potential upstream transcription factors of RAC3 were predicted and their interaction with RAC3 was confirmed via dual-luciferase and chromatin immunoprecipitation (ChIP) assays. T24/DDP, a cisplatin-resistant BCa cell line, was established to probe into the regulatory role of RAC3 in cisplatin resistance. Cell proliferation was evaluated by colony formation and the IC

Indexed as

Antineoplastic AgentsCisplatinDrug Resistance, NeoplasmFatty AcidsKruppel-Like Transcription Factorsrac GTP-Binding ProteinsUrinary Bladder NeoplasmsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsCisplatinerythroid Kruppel-like factorFatty AcidsKruppel-Like Transcription FactorsRAC3 protein, humanrac GTP-Binding Proteinsbladder cancercisplatin resistancefatty acid synthesisKLF1RAC3

Identifiers

PMID39376007
PMCPMC11459471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.